Teva and New Jersey Governor Murphy Formalize North America Headquarters Move with Ceremony in Israel
2018年10月21日 - 9:23PM
ビジネスワイヤ(英語)
Teva Pharmaceuticals announced that Teva executives Kåre Schultz
and Brendan O’Grady, alongside State of New Jersey Governor, Phil
Murphy, formalized Teva’s commitment to consolidate its North
America Commercial business areas into New Jersey (NJ) today at the
company’s global headquarters in Petach Tikva, Israel.
Announced earlier this year as part of a global restructuring
process, Teva will establish its North America headquarters in
Parsippany-Troy Hills, including more than 1,000 high-wage jobs and
the transfer and creation of more than 800 positions. Teva accepted
an offer of 10-year, $40 million tax savings incentives from the NJ
Economic Development Authority to move forward with its plan to
negotiate a lease for office space in the Parsippany-Troy Hills
area.
“We’re entering into a new era of innovation and growth as a
leading global generics and biopharmaceuticals company,” said
Brendan O’Grady, EVP and Head of North America Commercial, Teva.
“New Jersey offers Teva North America a value proposition of a
unique biopharma cluster of universities and life sciences
organizations in which Teva can build its future in North
America—and today’s event is an important recognition of this
milestone.”
This ceremony marks another step forward in Teva’s global
restructuring efforts to drive savings, restore financial security
and stabilize its business. Reducing the number of sites is part of
Teva’s strategy to unify and simplify the organization, as well as
improve productivity and efficiencies.
“We’re pleased to honor Teva today in recognition of its
long-time partnership and commitment to innovation in New Jersey,”
said Governor Murphy. “The presence of global life sciences
companies like Teva is critical to our ability to strengthen our
prosperous innovation ecosystem. We’re excited to welcome Teva to
the Garden State--the location to be for the world’s most
competitive life sciences companies.”
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a
global leader in generic medicines, with innovative treatments in
select areas, including CNS, pain and respiratory. We deliver
high-quality generic products and medicines in nearly every
therapeutic area to address unmet patient needs. We have an
established presence in generics, specialty, OTC and API, building
on more than a century-old legacy, with a fully integrated R&D
function, strong operational base and global infrastructure and
scale. We strive to act in a socially and environmentally
responsible way. Headquartered in Israel, with production and
research facilities around the globe, we employ 45,000
professionals, committed to improving the lives of millions of
patients. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements.
Important factors that could cause or contribute to such
differences include risks relating to:
- our ability to successfully compete in
the marketplace, including: that we are substantially dependent on
our generic products; competition for our specialty products,
especially COPAXONE®, our leading medicine, which faces competition
from existing and potential additional generic versions and
orally-administered alternatives; competition from companies with
greater resources and capabilities; efforts of pharmaceutical
companies to limit the use of generics including through
legislation and regulations; consolidation of our customer base and
commercial alliances among our customers; the increase in the
number of competitors targeting generic opportunities and seeking
U.S. market exclusivity for generic versions of significant
products; price erosion relating to our products, both from
competing products and increased regulation; delays in launches of
new products and our ability to achieve expected results from
investments in our product pipeline; our ability to take advantage
of high-value opportunities; the difficulty and expense of
obtaining licenses to proprietary technologies; and the
effectiveness of our patents and other measures to protect our
intellectual property rights;
- our substantial indebtedness, which may
limit our ability to incur additional indebtedness, engage in
additional transactions or make new investments, may result in a
further downgrade of our credit ratings; and our inability to raise
debt or borrow funds in amounts or on terms that are favorable to
us;
- our business and operations in general,
including: failure to effectively execute our restructuring plan
announced in December, 2017; uncertainties related to, and failure
to achieve, the potential benefits and success of our new senior
management team and organizational structure; harm to our pipeline
of future products due to the ongoing review of our R&D
programs; our ability to develop and commercialize additional
pharmaceutical products; potential additional adverse consequences
following our resolution with the U.S. government of our Foreign
Corrupt Practices Act investigation; compliance with sanctions and
other trade control laws; manufacturing or quality control
problems, which may damage our reputation for quality production
and require costly remediation; interruptions in our supply chain;
disruptions of our or third party information technology systems or
breaches of our data security; the failure to recruit or retain key
personnel; variations in intellectual property laws that may
adversely affect our ability to manufacture our products;
challenges associated with conducting business globally, including
adverse effects of political or economic instability, major
hostilities or terrorism; significant sales to a limited number of
customers in our U.S. market; our ability to successfully bid for
suitable acquisition targets or licensing opportunities, or to
consummate and integrate acquisitions; and our prospects and
opportunities for growth if we sell assets;
- compliance, regulatory and litigation
matters, including: costs and delays resulting from the extensive
governmental regulation to which we are subject; the effects of
reforms in healthcare regulation and reductions in pharmaceutical
pricing, reimbursement and coverage; governmental investigations
into sales and marketing practices; potential liability for patent
infringement; product liability claims; increased government
scrutiny of our patent settlement agreements; failure to comply
with complex Medicare and Medicaid reporting and payment
obligations; and environmental risks;
- other financial and economic risks,
including: our exposure to currency fluctuations and restrictions
as well as credit risks; potential impairments of our intangible
assets; potential significant increases in tax liabilities; and the
effect on our overall effective tax rate of the termination or
expiration of governmental programs or tax benefits, or of a change
in our business;
- and other factors discussed in our
Annual Report on Form 10-K for the year ended December 31, 2017,
including the sections thereof captioned "Risk Factors" and
"Forward Looking Statements," and in our subsequent quarterly
reports on Form 10-Q and other filings with the Securities and
Exchange Commission, which are available at www.sec.gov and
www.tevapharm.com. Forward-looking statements speak only as of the
date on which they are made, and we assume no obligation to update
or revise any forward-looking statements or other information
contained herein, whether as a result of new information, future
events or otherwise. You are cautioned not to put undue reliance on
these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181021005034/en/
Teva PharmaceuticalsIR ContactsUnited
StatesKevin C. Mannix, 215-591-8912orIsraelRan Meir,
215-591-3033orPR ContactsUnited StatesElizabeth
DeLuca, 267-468-4329orIsraelYonatan Beker, 972 (54) 888
5898
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024